Rx drug inactive ingredient listing
The Pharmaceutical Mfrs. Assn. has adopted a plan for its member companies to list inactive ingredients in alphabetical order in the package insert. Listing will be effective at time a member company next revises the drug insert or Dec. 1, 1985. Under the policy, companies may decline to list a particular inactive ingredient if disclosure would compromise trade secret information
You may also be interested in...
In a recent PR campaign for Calpol in the UK, Johnson & Johnson Consumer Health partnered with children’s charity NSPCC to raise awareness of the latter's helpline. HBW Insight speaks exclusively to J&J's head of Marketing for Northern Europe at J&J Consumer Health, Hannah French.
Suspension of heartburn remedy ranitidine looming in the EU as the European Medicines Agency stands by its original decision.
Novartis thwarts Sun’s efforts to commercialize nilotinib in India, though the Indian firm indicates that its actions are covered under a local Bolar-type provision and that it has no plans to market the oncology drug while the originator's patent stands valid.